Open Access

Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors

  • Authors:
    • Chao Liu
    • Quan Gong
    • Ting Chen
    • Juan Lv
    • Zhiping Feng
    • Pengjie Liu
    • Zhiyong Deng
  • View Affiliations

  • Published online on: January 24, 2018     https://doi.org/10.3892/ol.2018.7849
  • Pages: 4376-4382
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multidrug resistance (MDR) is an obstacle for cancer chemotherapy. It was reported that 20(S)-ginsenoside Rg3 (hereafter Rg3) was able to regulate MDR in mouse leukemia cells. The present study investigated the effect of Rg3 on the MDR of A549 lung cancer cells. A cell viability assay revealed that Rg3 treatment increased cisplatin (DDP) cytotoxicity in DDP resistant A549 cells (A549/DDP). Furthermore, Rg3 increases the antitumor effect of DDP on A549/DDP xenograft mice. The expression of MDR‑mediated proteins, including P‑glycoprotein (P‑gp), multidrug resistance‑associated protein (MPR1) and lung resistance protein 1 (LPR1), was detected in tumor tissue of A549/DDP xenograft mice. The results revealed that Rg3 treatment inhibited the expression of these MDR‑associated proteins. Additionally, technetium‑99m labeled hexakis-2-methoxyisobutylisonitrile (99mTc‑MIBI) single‑photon emission computed tomography was used to monitor the effect of Rg3 on cisplatin sensitivity of A549/DDP xenograft tumors. It was observed that uptake of 99mTc‑MIBI was increased by Rg3 treatment, which indicated that Rg3 is able to effectively enhance chemotherapy sensitivity of A549/DDP xenograft tumors. Taken together, these results revealed that Rg3 may be able to reverse MDR of lung cancer via the downregulation of P‑gp, MPR1 and LPR1.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu C, Gong Q, Chen T, Lv J, Feng Z, Liu P and Deng Z: Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors. Oncol Lett 15: 4376-4382, 2018
APA
Liu, C., Gong, Q., Chen, T., Lv, J., Feng, Z., Liu, P., & Deng, Z. (2018). Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors. Oncology Letters, 15, 4376-4382. https://doi.org/10.3892/ol.2018.7849
MLA
Liu, C., Gong, Q., Chen, T., Lv, J., Feng, Z., Liu, P., Deng, Z."Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors". Oncology Letters 15.4 (2018): 4376-4382.
Chicago
Liu, C., Gong, Q., Chen, T., Lv, J., Feng, Z., Liu, P., Deng, Z."Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors". Oncology Letters 15, no. 4 (2018): 4376-4382. https://doi.org/10.3892/ol.2018.7849